Rallybio

About:

Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease.

Website: http://rallybio.com/

Top Investors: F-Prime Capital, Connecticut Innovations, Viking Global Investors, The Rise Fund, Pivotal bioVenture Partners

Description:

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.

Total Funding Amount:

$239M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Farmington, Connecticut, United States

Founded Date:

2018-01-01

Founders:

Jeffrey Fryer, Martin Mackay, Stephen Uden

Number of Employees:

11-50

Last Funding Date:

2024-04-10

IPO Status:

Public

Industries:

© 2025 bioDAO.ai